Hospital
Nashville General Hospital
Nashville General Hospital was paid $7.87M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoNASHVILLE GENERAL HOSPITAL
NASHVILLE, TN 37208
NASHVILLE, TN 37208
33aNPI1568551455assigned 10/11/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.87M
24GClaims211,100
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#33 of 71
Median peer was paid$6.96M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,140 | $1.44M | |
| 2019 | 36,685 | $1.40M | |
| 2020 | 27,984 | $1.05M | |
| 2021 | 31,295 | $1.01M | |
| 2022 | 26,534 | $978K | |
| 2023 | 30,116 | $1.07M | |
| 2024incomplete | 22,346 | $926K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 14,904 | 12,615 | $2.58M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 16,660 | 14,360 | $2.14M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 46,076 | 36,069 | $1.38M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 3,340 | 2,622 | $789K |
| G0378 | Hospital observation service, per hour | 4.2% | 2,462 | 1,305 | $333K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 857 | 476 | $93K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,952 | 16,649 | $65K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 754 | 654 | $63K |
| 80053 | Comprehensive metabolic panel | <1% | 21,528 | 16,368 | $54K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,789 | 1,539 | $53K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 654 | 253 | $39K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,133 | 18,400 | $35K |
93 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,014 | $26K |
| 84484 | <1% | 3,130 | $24K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 1,003 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 475 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 488 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,082 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,081 | $7K |
| 80306 | <1% | 865 | $7K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 246 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,806 | $7K |
| 92134 | <1% | 1,163 | $7K | |
| 81001 | <1% | 11,466 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 161 | $6K |
| 81025 | <1% | 3,346 | $6K | |
| 20610 | <1% | 87 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 409 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,828 | $5K |
| 92002 | <1% | 194 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,298 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,191 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,059 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 423 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $3K |
| 90686 | <1% | 404 | $3K | |
| 80061 | Lipid panel | <1% | 900 | $3K |
| 85610 | <1% | 1,318 | $2K | |
| 85730 | <1% | 987 | $2K | |
| 85027 | <1% | 1,654 | $2K | |
| 82550 | <1% | 952 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 337 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 120 | $2K |
| 83880 | <1% | 320 | $2K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 122 | $2K |
| 81000 | <1% | 890 | $1K | |
| 96417 | <1% | 40 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 270 | $1K |
| 92250 | <1% | 44 | $1K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 18 | $1K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 15 | $1K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 36 | $1K |
| 92015 | Determination of refractive state | <1% | 281 | $1K |
| 87486 | <1% | 179 | $1K | |
| 87581 | <1% | 179 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 179 | $1K |
| 82652 | <1% | 188 | $964.81 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 181 | $878.07 |
| 84481 | <1% | 85 | $829.29 | |
| 87400 | <1% | 622 | $806.59 | |
| 84153 | <1% | 431 | $773.20 | |
| 82553 | <1% | 572 | $739.01 | |
| 84439 | <1% | 189 | $668.45 | |
| 83690 | <1% | 233 | $581.89 | |
| 87070 | <1% | 137 | $537.42 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 18 | $532.08 |
| 83735 | <1% | 244 | $493.08 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 173 | $485.78 |
| Q3014 | Telehealth originating site facility fee | <1% | 27 | $456.72 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $447.95 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $447.95 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 17 | $359.17 |
| 86769 | <1% | 39 | $320.00 | |
| 80074 | <1% | 12 | $296.09 | |
| 83605 | <1% | 48 | $282.34 | |
| 86160 | <1% | 14 | $233.38 | |
| 85651 | <1% | 106 | $218.22 | |
| 94664 | <1% | 63 | $214.70 | |
| 85014 | <1% | 284 | $214.27 | |
| 85018 | <1% | 284 | $211.81 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 63 | $202.83 |
| 80069 | <1% | 145 | $178.19 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44 | $152.28 |
| 84100 | <1% | 368 | $142.88 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 66 | $108.56 |
| 11721 | <1% | 16 | $103.95 | |
| 86140 | <1% | 52 | $92.38 | |
| 87205 | <1% | 59 | $89.04 | |
| 92020 | <1% | 24 | $78.09 | |
| 86225 | <1% | 12 | $71.48 | |
| 86256 | <1% | 12 | $70.16 | |
| 92133 | <1% | 29 | $68.56 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 15 | $58.85 |
| 11719 | <1% | 58 | $52.38 | |
| 81003 | <1% | 58 | $29.70 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 344 | $25.82 |
| 96376 | <1% | 36 | $10.70 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 32 | $10.60 |
| J2704 | Injection, propofol, 10 mg | <1% | 183 | $7.52 |
| 0064A | <1% | 17 | $0.05 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 218 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 12 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 19 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWEBB, JOSEPH (CHIEF EXECUTIVE OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Metropolitan Hospital Authority | Nashville, TN | $823K |
| Tennessee River Dermatology PC | Florence, AL | $316.15 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.